Johnson & Johnson steps up vaccines R&D—and prepares for launches—with €72M plant

Johnson & Johnson opened a new vaccine manufacturing plant in Leiden, the Netherlands, to support its candidates in development, and eventually, commercial rollouts. (J&J)

Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support its advancing pipeline candidates—and certainly not product launches down the road.

That's why the company targeted a new plant in Leiden, the Netherlands, for expansion. On Thursday, the drugmaker officially opened the site after four years of work. All told, J&J spent about €72 million on the plant, said Johan Van Hoof, Janssen global therapeutic area head of infectious disease and vaccines.